Mary Jean Stempien
Nessuna posizione attualmente
Profilo
Mary Jean Stempien served as Chief Medical Officer at CymaBay Therapeutics, Inc., Principal at Roche Pharmaceuticals, Inc., and Vice President-Clinical Development at Cerimon Pharmaceuticals, Inc. She obtained an undergraduate degree from the University of Connecticut, a doctorate from the University of Massachusetts, and a graduate degree from The University of California, San Francisco.
Precedenti posizioni note di Mary Jean Stempien
| Società | Posizione | Fine |
|---|---|---|
Cerimon Pharmaceuticals, Inc.
 Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
| CYMABAY THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Mary Jean Stempien
| University of Connecticut | Undergraduate Degree |
| The University of California, San Francisco | Graduate Degree |
| University of Massachusetts | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 3 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
- Borsa valori
- Insiders
- Mary Jean Stempien
